Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atazanavir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT1A1 | P22309 | 3/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | CCKAR | P32238 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | GHSR | Q92847 | 1/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.72 |
| ▸ | CTSD | P07339 | 4/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | CTSE | P14091 | 1/20 | 0.41 |
| ▸ | PGC | P20142 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 8/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 8/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 8/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atazanavir SCHEMBL7993264 | 1.00 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL41697 | 1.00 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL41696 | 1.00 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL9975220 | 1.00 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL1559640 | 1.00 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL20629941 | 1.00 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL21565117 | 1.00 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL20629937 | 1.00 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL22847477 | 1.00 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL1396072 | 1.00 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10869921-B2 | Compositions and methods to treat AIDS | UNIVERSITY OF MASSACHUSETTS (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190160165-A1 | COMPOSITIONS AND METHODS TO TREAT AIDS | UNIVERSITY OF MASSACHUSETTS | 2019-05-30 | — | — | US | disclosed |
| EP-3452483-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GlaxoSmithKline Intellectual Property (No. 2) Limited (GB) | 2019-03-13 | — | — | EP | disclosed |
| EP-3384040-A1 | COMPOSITIONS FOR CYP450 PHENOTYPING USING SALIVA SAMPLES | Concordia University, Inc. (US) | 2018-10-10 | — | — | EP | disclosed |
| WO-2017191545-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-11-09 | — | — | WO | disclosed |
| WO-2017095921-A1 | COMPOSITIONS FOR CYP450 PHENOTYPING USING SALIVA SAMPLES | CONCORDIA UNIVERSITY INC. (US) | 2017-06-08 | — | — | WO | disclosed |
| US-20160038502-A1 | HIV TREATMENT FORMULATION OF ATAZANAVIR AND COBICISTAT | BRISTOL-MYERS SQUIBB COMPANY | 2016-02-11 | — | — | US | disclosed |
| WO-2012006353-A1 | DRUG-ELUTING CERVICAL CAP | CERMED CORPORATION (US) | 2012-01-12 | — | — | WO | disclosed |
| EP-2190461-A2 | USE OF PARATHYROID HORMONE (1-34) AS ANTI-HIV AGENT | Mondobiotech Laboratories AG (LI) | 2010-06-02 | — | — | EP | disclosed |
| EP-2187934-A1 | USE OF FERTIRELIN AND DELTA-ENDORPHIN AS THERAPEUTIC AGENTS | Mondobiotech Laboratories AG (LI) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009033663-A1 | USE OF FERTIRELIN AND DELTA-ENDORPHIN AS THERAPEUTIC AGENTS | MONDOBIOTECH LABORATORIES AG (LI) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009033667-A2 | USE OF A PEPTIDE AS A THERAPEUTIC AGENT | MONDOBIOTECH LABORATORIES AG (LI) | 2009-03-19 | — | — | WO | disclosed |
| WO-2008112156-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008109154-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2007010266-A1 | PYRROLIDINE COMPOSITIONS | MNL PHARMA LIMITED (GB) | 2007-01-25 | — | — | WO | disclosed |
| WO-2006129134-A1 | SYNERGIC COMBINATIONS COMPRISING A STYRYLQUINOLINE COMPOUND AND OTHER HIV INFECTION THERAPEUTIC AGENTS | BIOALLIANCE PHARMA (FR) | 2006-12-07 | — | — | WO | disclosed |
| US-7135467-B2 | Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-14 | — | — | US | disclosed |
| WO-2006077427-A2 | ANTIVIRAL DRUG COMBINATIONS | MNL PHARMA LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| US-20040204498-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
| WO-2004062613-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204498-A1 | HIV integrase inhibitors | IMPDH1, TYMP, REV1 | UGT1A1 319/4885MLNR 3936/4885NR1I2 838/4885 |
| US-20160038502-A1 | HIV TREATMENT FORMULATION OF ATAZANAVIR AND COBICISTAT | APOBEC3A, SAMHD1, ADA | UGT1A1 1305/4885MLNR 3972/4885NR1I2 3781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.